NanoSyrinx
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy,safety, and economy.
Coventry, UKwww.nanosyrinx.com ↗
Total raised
€19M
€19,077,748
Funding rounds
2
Investors
10
distinct backers
Active since
2021-07
latest 2024-09
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood37
base rate 30% for Other
- ▲ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood12
base rate 12% (2+ rounds)
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-09-10 | Other | €12M | BGF,Eli Lilly,IQ Capital,M Ventures ,Meltwind,Octopus Ventures | View deal → |
| 2021-07-19 | Seed | €7.2M | BioCity,IQ Capital,Jonathan Milner.,M Ventures,Octopus Ventures,UK Innovation & Science Seed Fund | View deal → |